Authors: Joseph R. Peterson, PhD1, Brandy Wolff1, Bradley Feiger, PhD1, Vignesh Kannan, MS1, Katrina Rabinovich, MD2, Stefanie A. Woodard, DO3, Kathryn W. Zamora, MD, MPH3 1SimBioSys, Inc., Chicago, IL, USA; 2Mount Sinai Medical Center, Miami, FL, USA; 3University of Alabama-Birmingham,…
Authors: Vincent J. Reid, MD, FACS1, Linsey P. Gold, DO, FACOS, FACS2, Eric A. Brown, MD, FACS2, Allison A. DiPasquale, MD3, Anne G. Peled, MD4, Joseph R. Peterson, PhD5, Barry S. Rosen, MD5,6 1Mercy, Cedar Rapids, IA, USA; 2Comprehensive Breast…
Company to share fresh vision and transformative plans for its next chapter at the J.P. Morgan Healthcare Conference CHICAGO, IL – January 9, 2025 – SimBioSys, a pioneering TechBio company revolutionizing cancer care with advanced AI and spatial biophysics, today…
CHICAGO–(BUSINESS WIRE)–SimBioSys®, a trailblazing TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine cancer precision medicine, transform patient care and defeat cancer today announced the strategic appointment of Jyoti Palaniappan as Chief Commercial Officer…
-TumorSight™ is a cloud-based digital precision medicine platform intended to support the end-to-end patient journey -TumorSight™ Viz, the first FDA cleared TumorSight™ application, provides clinicians with key 3D spatial visualizations of the tumor and surrounding tissue to bring imaging to…
January 02, 2024 07:00 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, announced today it has entered into a strategic…
December 18, 2023 07:00 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and biophysical modeling to redefine precision medicine for cancer, announced today it has entered a strategic collaboration…
Decision-making for early (Stages 1-3) breast cancer (eBC) surgery is complex and highly personal, requiring discussions between patients and multiple physicians. Shared decision-making (SDM) is an accepted process but its use by physicians is low due to a lack of time, incentives, complicated applications, and few communication tools. SimBioSys…
Neoadjuvant therapy (NAT) has become a standard-of-care (SOC) for patients diagnosed with locally advanced or early-stage breast cancer. While pathological complete response (pCR) is commonly used to measure NAT effectiveness, patients who do not achieve pCR may still benefit from NAT, depending on the tumor’s response. A reduction…
The decision-making process regarding breast cancer treatment options, specifically breast conserving surgery (BCS) versus mastectomy, is a complex and sensitive matter that takes into account the patient’s preferences and the surgeon’s clinical opinion. A range of anatomical factors, such as tumor size, breast size,…